SCHEMBL1483458

SCHEMBL1483458

NC(=O)Cc1ncc2ccccc2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 4/20 0.47
BCHE P06276 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.41
HTT P42858 1/20 0.41
ALDH1A1 P00352 2/20 0.40
IKBKB O14920 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
FDPS P14324 1/20 0.40
KDM4E B2RXH2 3/20 0.38
MGAM O43451 2/20 0.38
PLAU P00749 1/20 0.38
LMNA P02545 1/20 0.38
PKM P14618 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
CYP1A2 P05177 1/20 0.37
MAP3K5 Q99683 1/20 0.37
RAB9A P51151 1/20 0.36
GPR3 P46089 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5623659 0.84 KDM4E (0.49) SMN1; SMN2ALDH1A1GAAMAPTFDPS
SCHEMBL17924548 0.83 SMN1; SMN2 (0.39) ACHEBCHESMN1; SMN2ALDH1A1IKBKB
SCHEMBL2732701 0.83 NPSR1 (0.41) ACHEALDH1A1IKBKBMAPTFDPS
SCHEMBL2562160 0.80 HTT (0.39) ACHEBCHEHTTALDH1A1MAPT
SCHEMBL15718168 0.80 ACHE (0.42) ACHEBCHESMN1; SMN2HTTALDH1A1
SCHEMBL28318696 0.79 ALDH1A1 (0.48) SMN1; SMN2ALDH1A1MAPTKDM4EPKM
SCHEMBL17240997 0.78 ALDH1A1 (0.36) ACHEBCHESMN1; SMN2ALDH1A1IKBKB
SCHEMBL28754731 0.77 KDM4E (0.37) ACHEALDH1A1MAPTFDPSKDM4E
SCHEMBL6597830 0.76 SORD (0.47) ACHEALDH1A1GAAMAPTFDPS
SCHEMBL9934866 0.76 KDM4E (0.42) ACHEALDH1A1MAPTFDPSKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015155306-A1 NEW TRPA1 ANTAGONISTS ALMIRALL, S.A. (ES) 2015-10-15 WO claimed
US-20230416205-A1 COMPOUNDS, COMPOSITIONS, AND METHODS TENVIE THERAPEUTICS, INC. 2023-12-28 US disclosed
WO-2015155306-A1 NEW TRPA1 ANTAGONISTS ALMIRALL, S.A. (ES) 2015-10-15 WO disclosed
US-8431556-B2 C-21-keto lupane derivatives preparation and use thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-30 US disclosed
US-7951814-B2 Quinazolinedione derivatives as TRPA1 modulators GLENMARK PHARMACEUTICALS, S.A. (CH) 2011-05-31 US disclosed
US-20110077228-A1 NOVEL C-21-KETO LUPANE DERIVATIVES PREPARATION AND USE THEREOF MOINET CHRISTOPHE 2011-03-31 US disclosed
WO-2010004390-A1 QUINAZOLINE DIONE DERIVATIVES AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS, S.A. (CH) 2010-01-14 WO disclosed
US-20090325987-A1 QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS, S.A. (CH) 2009-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230416205-A1 COMPOUNDS, COMPOSITIONS, AND METHODS NLRP3, NLRP1, NOD1 ACHE 4836/4885BCHE 4322/4885SMN1; SMN2 4168/4885
US-20090325987-A1 QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS TRPA1, TRPV1, TRPC3 ACHE 2051/4885BCHE 4077/4885SMN1; SMN2 4097/4885
US-20110077228-A1 NOVEL C-21-KETO LUPANE DERIVATIVES PREPARATION AND USE THEREOF CYP51A1, CYP17A1, HSD17B7 ACHE 4842/4885BCHE 3849/4885SMN1; SMN2 4262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.